In today’s Pharmaceutical Executive Daily, the FDA approves Novo Nordisk’s oral Wegovy for chronic weight management, clears Roche’s Lunsumio Velo for adults with relapsed or refractory follicular lymphoma, and Alnylam announces a $250 million investment in a new Massachusetts manufacturing facility.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today’s Pharmaceutical Executive Daily, the FDA approves Novo Nordisk’s oral Wegovy for chronic weight management, clears Roche’s Lunsumio Velo for adults with relapsed or refractory follicular lymphoma, and Alnylam announces a $250 million investment in a new Massachusetts manufacturing facility.
The FDA has approved Novo Nordisk’s oral formulation of Wegovy for chronic weight management, marking a significant expansion of GLP-1–based obesity treatments beyond injectable options. The decision could broaden patient access while intensifying competition across the rapidly growing metabolic disease market.
In oncology news, the FDA has approved Lunsumio Velo, a ready-to-administer formulation of Roche’s bispecific antibody mosunetuzumab, for adults with relapsed or refractory follicular lymphoma. The streamlined delivery is designed to reduce preparation time and operational burden for treatment centers.
And in manufacturing and infrastructure news, Alnylam Pharmaceuticals has announced a $250 million investment to expand its Massachusetts operations. The new facility will support commercial-scale manufacturing and reinforce the company’s long-term commitment to RNAi-based therapies.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
